Revolution Medicines (RVMDW) Profit After Tax (2019 - 2026)

Revolution Medicines' Profit After Tax history runs 8 years deep, the most recent figure standing at -$453.8 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 112.64% year-over-year to -$453.8 million; the TTM figure through Mar 2026 stood at -$1.4 billion (down 96.38% YoY), while the FY2025 annual figure was -$1.1 billion, down 88.2% from the prior year.
• Profit After Tax for Q1 2026 stood at -$453.8 million, down from -$363.0 million in the prior quarter.
• The five-year high for Profit After Tax was -$56.5 million in Q4 2022, with the low at -$453.8 million in Q1 2026.
• The 5-year median for Profit After Tax is -$133.2 million (2024), against an average of -$168.6 million.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax slipped 6.28% in 2022, then sank 181.76% in 2023.
• Revolution Medicines' Profit After Tax stood at -$56.5 million in 2022, then tumbled by 181.76% to -$159.2 million in 2023, then fell by 22.21% to -$194.6 million in 2024, then sank by 86.55% to -$363.0 million in 2025, then retreated by 25.03% to -$453.8 million in 2026.
• Business Quant data shows RVMDW's Profit After Tax at -$453.8 million in Q1 2026, -$363.0 million in Q4 2025, and -$305.2 million in Q3 2025.